Women's Health Research Funding in Canada across 13 years suggests low funding levels with a narrow focus

Laura L Gravelsins, Tallinn FL Splinter, Ahmad Mohammad, Samantha A Blankers, Gabrielle L. Desilets, Liisa AM Galea*

***Corresponding Author:**
Liisa Galea, Ph.D.,
Treliving Family Chair in Women's Mental Health, Senior Scientist
Centre for Addiction and Mental Health, 250 College Street, Toronto, ON,
M5T 1R8, Canada
Phone: 416-535-8501 x33943
liisa.galea@utoronto.ca

Author affiliations:

1. Campbell Family Mental Health Research Institute, Center for Addiction and Mental Health, Toronto, ON, Canada
2. Rehabilitation Sciences Institute, University of Toronto, Toronto, ON, Canada
3. Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada
4. Department of Psychiatry, University of Toronto, Toronto, ON, Canada
5. Department of Psychology, University of Toronto, Toronto, ON, Canada

Abstract

Background: Women's health has historically been undervalued, underrepresented, and underfunded. Sex and gender mandates were introduced in grant competitions to increase women's health research. This study aimed to understand what type of women's health research is being funded and prioritized in open grant competitions in Canada. **Methods:** Publicly available funded Canadian Institute of Health Research (CIHR) project grant abstracts from 2020 and 2023 were coded for the mention of sex, gender, two-spirit, lesbian, gay, bisexual, trans, queer plus (2S/LGBTQ+), and female-specific research and assessed for changes in research representation and funding. A deeper analysis of funded female-specific grant abstracts from 2023 and 2009-2020 was conducted to assess if grant abstracts focused on the 11 areas of global disease burden and death that disproportionately affect females, and if this has evolved over time. **Results:** The percentage of abstracts mentioning sex, gender and 2S/LGBTQ+ doubled or quadrupled from 2020 to 2023, but remained at under 10% of overall funded abstracts. In contrast, female-specific research representation did not change over time, and remained at ~7% of all research. Importantly, female-specific research largely focused on cancers (breast, gynecologic) or pregnancy. We also examined research funding representation for the top 11 global burden of disease or death for females across the 13 years and observed that cancer accounted for 2.07% of funding, whereas the other top 10 collectively accounted for 2.21% across 13 years. **Conclusions:** Despite mandates for integrated sex and gender based analyses in Canada, research acknowledging which population is explored remains under 10%. Mandates are not affecting the percentage of funding for women's health grants. More efforts and support beyond sex and gender mandates are needed to increase funding for and to diversify female-specific research beyond pregnancy and cancer. Research devoted to women's health factors is key to achieving personalized medicine and improved health outcomes for everyone.

Keywords

CIHR, Female, LGBTQ, sex, gender, SABV, SGBA

Introduction

Women experience delays in diagnoses, misdiagnoses, and a greater percentage of adverse effects towards new therapeutics than men (Westergaard et al., 2019; Zucker & Prendergast, 2020). Across nearly 1300 of the same diseases and health conditions, females are diagnosed on average 2 years later than males (Westergaard et al., 2019), and women spend 25% more time in poor health and with disability compared to men (*Closing the Women's Health Gap to Improve Lives and Economies*, n.d.). These disparities stem, in part, from a lack of research in women's health (Mirin, 2021; Stranges et al., 2023). The paucity of women's health research may be due to misconceptions held by researchers, regulators and funders. These misconceptions may include the belief that human females are "too complex" to research compared to human males due to fluctuating ovarian hormones, that human males and females are similar in their physiological responses to treatments and disease endophenotypes, and concerns that reproductive fitness will be negatively affected due to research. However, human males experience a daily decline of testosterone by approximately 50% (Cooke et al., 1993), indicating dramatic fluctuations in testicular hormones. Moreover, dramatic sex differences are seen in gene expression and physiological responses to drugs and disease - often in opposing directions - indicating that basic physiological mechanisms differ between the sexes (Blokland et al., 2022; Seney et al., 2018; Tesfaye et al., 2024). Lastly, the exclusion of pregnant females in early trials of COVID-19 vaccines delayed vaccine uptake, even though later research showed pregnant females and the fetus benefit from the vaccine and pregnant females are at 2.5 greater times likely to die from contracting COVID-19 (Galea et al., 2023; Gonçalves et al., 2021). Indeed, sex chromosomes (XX, XY) are present in every nucleated cell across the body, and hormone receptors (ER, PR) are located in every organ, not only reproductive organs (Gravelsins & Galea, in press). New data indicates that X and Y complement can significantly impact health in varied ways including the existence of XIST (X-inactive specific transcript) (Maan et al., 2017; Wang et al., 2021). Thus, multiple lines of evidence indicate that sex needs to be considered in health and medicine.

Across a variety of diseases, there are sex differences in their underlying biological mechanisms, manifestation, symptomatology, and treatment (Galea et al., 2023). These findings suggest that we need to understand why and how these differences exist in women - what

contributes to differences in susceptibility but also in manifestation as this suggests treatment options need to be tailored. However, women's health receives significantly less research representation and funding outside of reproductive or sexual health or "bikini medicine" (Wenger, 2021). Moreover, in pregnancy research, outcomes on the birthing parents are often ignored, with the focus squarely on the fetus or offspring, whereas pregnancy effects on the mother/birthing parent are disregarded (Fisk & Atun, 2009). Indeed, the top global burdens of disease in women have been identified as low back pain, depressive disorders, headache disorders, anxiety, musculoskeletal disorders, Alzheimer's disease and other dementias, and HIV/AIDS (Patwardhan et al., 2024). The top global burdens of death in women have been identified as cardiovascular diseases (CVDs), diabetes, cancers and respiratory diseases (Peters et al., 2016). Although women live longer than men, they are also 25% more likely to live with chronic illness (*Closing the Women's Health Gap to Improve Lives and Economies*, n.d.). These facts suggest that research in women's health must be broader and consider these diseases to achieve "gender equity" in health research and knowledge. Yet research in women's health beyond reproductive health is sparse (Hallam et al., 2022), adding to the disparities in health research and delays in appropriate treatments. Research funding needs to acknowledge that women's health goes beyond bikini medicine.

Over 30 years ago, the National Institutes of Health (NIH) issued guidelines that required the inclusion of women and minorities in clinical trial research, however to this day ~ 50% of NIH-funded randomised control trials research does not include sex as a variable in the analyses, and the 50% includes the use of sex as a covariate, which does not explicitly test to determine if sex influences the results (Koch et al., 2024). Efforts to protect women's health research and funding are essential to achieve precision medicine, which will allow for faster diagnoses and treatments in women, gender diverse individuals, and men. "Lazeroids", a series of compounds effective in limiting brain damage in ischemic strokes, were rejected by the Food and Drug Administration in 1999 as a potential therapeutic, as it was not effective in a mixed-sex trial. However, when analyzing the data by sex, "lazeroids" were beneficial only for male patients (Cahill, 2018). Had this been examined at the time, it could have been used to improve stroke outcomes in males. Critically, researching using sex as a meaningful variable in outcomes improves personalized medicine and health outcomes for men, not just for women. The use of

sex as a meaningful or discovery variable can improve power and improve diagnostic accuracy (Mersha et al., 2015; Sundermann et al., 2019, 2021; Tesfaye et al., 2024).

In 2010, the Canadian Institute of Health Research (CIHR) first implemented mandatory fields to indicate whether a project studied and analyzed sex or gender as part of their funding application process. In 2019, CIHR introduced grant scoring for sex- and gender-based analysis (SGBA). Analyzing funding trends over time provides insight into what research is prioritized and whether SGBA frameworks introduced by major funding bodies are effective for promoting change. Despite CIHR mandates, under 10% of funded grant abstracts mentioned female, sex, gender, or S2/LGBTQ+ health in 2019 and there was a less than 2.2 % increase over the 12 years (2009-2019) examined across all categories (Stranges et al., 2023). Aligned with these findings, a survey of the biomedical literature suggests few publications (5%) are examining sex or gender as a factor in their analyses, despite a greater percentage (68%) of publications reporting on the use of males and females or men and women (Garcia-Sifuentes & Maney, 2021; Kilpatrick et al., 2023; Rechlin et al., 2022). Out of 251 neuroimaging studies prior to 2020 that included both males and females, 80% did not analyse with sex as a factor or used statistical methodologies to eliminate the effect of sex (Duffy & Epperson, 2022). Of the studies that investigated sex differences, 72% found a significant effect in at least one outcome variable, suggesting that sex is a meaningful biological variable that can facilitate scientific discovery in psychiatric research. This is important as mental health conditions of depression and anxiety are in the top global burden of diseases for women (Patwardhan et al., 2024).

Sex and gender mandates were ostensibly created to improve our knowledge of women's health, however, it is important to recognise that both across sex and gender, as well as within sex and gender research is needed. Importantly, female health extends beyond sex difference research (i.e., research considering how females differ from males). It requires us to incorporate female-specific experiences, including the menstrual cycle, hormonal contraception, pregnancy, postpartum, and menopause, into our research on health and disease (Galea et al., 2023). Thus, female-specific research, i.e., research conducted using only female subjects/participants, is necessary to help us move beyond merely understanding what sex differences exist. For example, new therapeutics were recently identified for postpartum depression and nausea and vomiting during pregnancy. Brexanalone, a synthetic allopregnanolone, was approved in 2019 by

the federal drug administration for postpartum depression, due to dedicated biomedical research on postpartum depression (Walton & Maguire, 2019). The recent identification of growth differentiation factor 15 (GDF15) as the culprit for nausea and vomiting during pregnancy will also lead to new therapeutics for those at risk for adverse events during pregnancy (Fejzo et al., 2024). To serve approximately 50% of the population, female-specific health knowledge is essential. Moreover, closing the women's health gap would have significant global economic benefits, boosting the global economy by at least $1 trillion annually by 2040 (*Closing the Women's Health Gap to Improve Lives and Economies*, n.d.). Only 6.6% of CIHR funding identified a female -specific question in their public abstract (Stranges et al., 2023), and these results suggest that the SGBA or Sex as a Biological Variable (SABV) mandates are not stimulating women's health research. These mandates also ignore that *within* sex comparisons, not just *across* sex comparisons, are important to understand factors important in medical research. With this in mind we wanted to understand what type of women's health research is being funded in open grant competitions in Canada.

Examining funding trends over time provides key insight into what research is prioritized and funded. This study aimed to understand what populations and topics in women's health were being funded by CIHR, building upon our past analyses of the CIHR funding decisions database. Publicly available funded CIHR project grant abstracts from 2023 were assessed for the mention of population used for the research with attention paid to sex, gender, two-spirit, lesbian, gay, bisexual, trans, queer plus (2S/LGBTQ+), and female-specific research, and compared to funded CIHR project grant abstracts from 2020 using the same criteria. Finally, we also analysed topics of funded female-specific grant abstracts from over 13 years from 2009 to 2023. We were particularly interested in whether funded female-specific CIHR grant abstracts focused on the 11 areas of global disease burden and death that disproportionately affect females, and if this has evolved over time.

Methods

We reviewed publically available abstracts of Project Grants funded by the CIHR in 2023 using the CIHR Funding Decisions Database (CIHR Government of Canada, 2008). Project grants are similar to the R01 mechanism at NIH and are open competitions that fund investigator-driven health research projects (https://cihr-irsc.gc.ca/e/49051.html). Prior to 2016,

Project Grants were referred to as Operating Grants. To identify relevant grant abstracts, female-related search terms were used. Female-related search terms were consistent with a previous study (Stranges et al., 2023): female, woman, women, uterus, uter, pregnan, breast, ovary, ovarian, ovaries, girl, menopause, postpartum, maternal, placenta, cervi, vagin, FSF, binary, lesbian, gay, bisexual, queer, LGBT, LGBTQ, LGBTQIA, LGBTQIA□+, LGB, transgender, transsex, trans, 2S, two spirit, 2 spirit, indigi (indigiqueer).

Grant abstracts in both English (*n* = 754) and French (*n* = 14) were examined and coded (described below). French abstracts were translated using the Google translate tool, and then coded.

Funded grant abstracts were coded as mentioning using populations that were female-specific, 2S/LGBTQ+, related to sex, and/or gender. Coding was completed by LLG and TFLS and grant abstracts that did not clearly fall into one of these categories were discussed. LLG reviewed all coding. Grant abstracts proposing research across more than one category were double coded. A liberal approach was adopted, such that any grant abstracts that mentioned including males and females, even though analyzing by sex was not explicitly mentioned in an analysis plan, were counted as investigating possible sex differences. Grants were coded as female-specific if the abstract mentioned studying females only. To assess if a sex bias existed in female-specific research, nominated principal investigator first names were classified as female-inferred or male-inferred. This classification was determined by consulting the investigator's personal website or, when unavailable, using an online search tool (https://genderize.io/).

To determine if certain areas of female-specific health received more research representation and funding, female-specific abstracts were categorized according to their research area and grouped for a thematic analysis. Of particular interest was whether female-specific abstracts focused on the 11 causes of global disease burden and death that have disproportionately affected females over the past three decades (Patwardhan et al., 2024; Peters et al., 2016), and whether this focus has shifted over time. Thus, female-specific grants from 2009-2020 and 2023 were coded as to whether they focused on low back pain, depressive disorders, headache disorders, anxiety, musculoskeletal disorders, Alzheimer's disease and other dementias, HIV/AIDS, CVDs, respiratory diseases, diabetes and cancer. The 517 female specific

grants from 2009-2020 that were previously identified in Stranges et al. (2023) were further coded into the categories as described above. All new coding was completed by LLG, TFLS, AM, SAB, GLD.

Statistical analyses

The percentage of funded grants belonging to a given category, as a function of the total number of awarded grants (n = 768 from 2023; n = 699 from 2020), was calculated. The percentage of funding dollars, as a function of the total funding dollars allocated to the funded grants ($651,948,708 from 2023; $527,933,841 from 2020), was analyzed. All statistical analyses were conducted in RStudio version 4.3.1. Z-tests for proportions using the prop.test() function from the stats package were used to evaluate if there was significant change from 2020 to 2023 in the percentage of grant abstracts that mentioned studying sex, gender, 2S/LGBTQ+, were female specific, or did not mention sex/gender as well as the percentage of funding dollars allocated to these same categories. To correct for multiple tests, the p.adjust() function from the stats package was used to apply the false discovery rate (FDR) correction. Cohen's h was calculated as a measure of effect size for each z-test.

To assess if a sex bias existed in grants that mentioned 2S/LGBTQ+, a Fisher's exact test was conducted to compare the proportion of 2S/LGBTQ+ grants devoted to sexually-/gender-diverse (e.g. gay, queer, bisexual, trans) men and women (Namchuk et al., 2025) using the fisher.test() function from the stats package. To assess if a sex bias existed in female-specific research, a Chi-square test was conducted to compare the proportion of female-specific grants with a nominated principal investigator female-inferred or male-inferred first name using the chisq.test() function from the stats package. Cramer's V was calculated as a measure of effect size.

Separate analyses were conducted on the female-specific grants from 2009-2020 (n = 517), and 2023 (n = 55). Simple linear regressions were run using the lm() function from the stats package to investigate if there were differences in the percentage of female-specific grants dedicated to the eleven causes of global disease burden that disproportionately affect females, and if there were differences in the percentage of funding dollars dedicated to these causes of global disease burden. Post hoc pairwise comparisons were conducted using the emmeans()

function from the emmeans package with Tukey's adjustment for multiple comparisons, as we were interested in all comparisons. The eff_size() function from the effectsize package was used to obtain Cohen's *d* for each comparison. Separate linear regressions were used to investigate if the percentage of female-specific grant abstracts mentioning each cause of global disease burden, and the percentage of funding dollars dedicated to each cause of global disease burden, changed over time. To correct for multiple tests, the p.adjust() function from the stats package was used to apply the FDR correction. Statistical significance was set to $p < 0.05$ for all tests. Partial eta squared was calculated as a measure of effect size for each linear model.

Results

In total, there were 775 project grants that received CIHR funding in 2023. Of these, 7 were bridge grants/funding extensions for $100,000. Bridge grants were removed, leaving a total of 768 unique project grants that received a total of $651,948,708 in research funding. In 2023, the average project grant received $848,892 in research funding.

The percentage of grant abstracts mentioning sex or gender doubled in 2023 from 2020 at 5.5% and 1.7% respectively, whereas grant abstracts mentioning 2S/LGBTQ+ quadrupled during that same time period to 1.8% of the total grant abstracts funded.

Compared to 2020, significant improvements were noted in nearly each category of our analysis, with the exception of female health. The percentage of funded grant abstracts that mentioned sex significantly increased, nearly doubling from 2.86% in 2020 to 5.47% in 2023 ($z = 2.48$, $p = 0.013$, 95% CI: [0.58%, 4.64%]). Similarly, the percentage of grant abstracts that mentioned gender significantly increased, nearly tripling from 0.57% in 2020 to 1.69% in 2023 ($z = 2.00$, $p = 0.045$, 95% CI: [0.05%, 2.19%]). Moreover, the percentage of grant abstracts that included 2S/LGBTQ+ significantly increased, quadrupling from 0.43% in 2020 to 1.82% in 2023 ($z = 2.49$, $p = 0.013$, 95% CI: [0.33%, 2.46%]). Consistent with this, the percentage of grant abstracts that did not mention sex/gender of the populations to be studied significantly decreased from 90.41% in 2020 to 85.42% in 2023 ($z = -2.92$, $p = 0.003$, 95% CI: [-8.31%, -1.68%]) (Figure 1A).

The percentage of grant abstracts mentioning female-specific populations did not significantly change from 2020 to 2023 at 7% of all grant funding.

Unlike the increases seen in grant abstracts mentioning sex, gender, or 2S/LGBTQ+ populations, the percentage of grant abstracts that were female-specific did not significantly increase from 2020 to 2023 ($z = 0.44$, $p = 0.66$, 95% CI: [-2.01%, 3.17%]). Female-specific grant abstracts accounted for 7.16% of funded research project grants in 2023, which was only a 0.58% increase from 6.58% of funded research project grants in 2020. When female-specific grant abstracts investigating cancer were removed, there was no significant increase in the percentage of female-specific grant abstracts in 2023 from 2020 (4.01% in 2020 to 4.95% in 2023 : $z = 0.87$, $p = 0.38$, 95% CI: [-1.17%, 3.06%]).

Funding totals for grant abstracts mentioning sex or gender doubled in 2023 from 2020, whereas grant abstracts mentioning 2S/LGBTQ+ quadrupled during that same time period.

Increases in funding from 2020 to 2023 amounts largely paralleled findings of representation. The percentage of funding allocated to grants that mentioned sex of the population significantly increased, more than doubling from 2.33% in 2020 to 5.82% in 2023 (3.49% increase; $z = 2951.56$, $p < 0.001$, 95% CI: [3.47%, 3.49%]). The percentage of funding allocated to grants that mentioned gender significantly increased, quadrupling from 0.31% in 2020 to 1.37% in 2023 (1.06% increase; $z = 1926.76$, $p < 0.001$, 95% CI: [1.061%, 1.063%]). The percentage of funding allocated to grants that included 2S/LGBTQ+ populations significantly increased, nearly quadrupling from 0.46% in 2020 to 1.73% in 2023 (1.27% increase; $z = 2020.18$, $p < 0.001$, 95% CI: [1.267%, 1.270%]). Consistent with this, the amount of funding allocated to grant abstracts that did not mention sex/gender significantly decreased from 90.83% in 2020 to 85.97% in 2023 (4.8% decrease; $z = -2563.96$, $p < 0.001$, 95% CI: [-4.86%, -4.85%]) (Figure 1B).

Although small in magnitude, the percentage of funding allocated to grants that were female-specific significantly increased from 6.84% in 2020 to 7.05% in 2023 (0.21% increase; $z = 139.76$, $p < 0.001$, 95% CI: [0.205%, 0.211%]). When female-specific grant abstracts investigating cancer were removed, the percentage of funding allocated to grants that were female-specific significantly increased from 4.00% in 2020 to 4.88% in 2023 (0.88% increase; $z = 729.79$, $p < 0.001$, 95% CI: [0.882%, 0.887%]).



Figure. 1. An infographic depicting the change in percentage of grants and funding between 2020 and 2023 for awarded Canadian institutes of Health Research (CIHR) grants for the different categories. The change in percentage (%) of grants (A) and funding amount (B) in the years 2020 and 2023 that did not mention of sex and gender in their grant abstracts or mentioned female-specific health, female-specific health not including cancer based grants, sex, gender, or 2S/LGBTQ + health.

Twice as many grants that studied S2/LGBTQ+ persons were focused on male-specific research questions compared to female-specific

Only 1.82% of funded project grants (14 of 768) focused on 2S/LGBTQ+ persons. Of these, 28.57% focused on sexually-/gender-diverse (e.g. gay, queer, bisexual, trans) men and 14.29% focused on sexually-/gender-diverse (e.g. lesbian, queer, bisexual, trans) women, suggesting that a male bias also exists in research focused on S2/LGBTQ+ persons. Although 2S/LGBTQ+ research focusing on sexually-/gender-diverse men was double that of sexually-/gender-diverse women, the proportion difference was not statistically significant (*OR* = 2.33, *p*-value = 0.65, 95% CI: [0.27 to 30.87]).

Most female-specific project grants from 2023 focused on cancer and pregnancy. All

female-specific project grants on cancer in 2023 were focused on breast and/or ovarian cancer.

To determine what female-specific research was being investigated, a thematic analysis was conducted on all female-specific grants in 2023. A thematic analysis revealed that the majority (60%) of female-specific project grant abstracts from 2023 focused on cancer (36.4%) and pregnancy (23.6%; Figure 2). Out of the twenty project grants that examined cancer, all focused on breast and/or ovarian cancer; only one of these project grants additionally focused on pancreatic cancer along with breast cancer. Fewer were devoted to health conditions that only affect females; endometriosis (7.3%), polycystic ovary syndrome (PCOS; 1.8%), vaginismus (1.8%), pelvic floor weakness (1.8%), and vestibulodynia (1.8%), collectively accounted for 14.5% of the female-specific project grants. To be clear, grant abstracts mentioning endometriosis were 0.52% of the *total* grants awarded in 2023 (4 of 768). Aside from pregnancy, even fewer were devoted to life factors that affect females; hormonal birth control (1.8%), postpartum (3.6%), and menopause (5.5%), collectively accounted for 10.9% of the female-specific project grant abstracts or 0.78% or total abstracts funded in 2023 (6 of 768). The nominated principal investigators of the female-specific grants from 2023 were more likely to have female-inferred first names (58.82%; n = 50) than male-inferred first names (41.18%; n =



35) , ($X^2(1) = 4.61$, $p = 0.032$).

Figure 2. Breakdown of female-specific (7.2%) CIHR funded project grant abstracts in 2023 by theme. Theme breakdowns are given as a proportion of female-specific grant abstracts in red. Created in https://BioRender.com

Longitudinal analysis of female-specific grant abstracts

We next examined all the female-specific grant abstracts over the 13 years analyzed (2009-2020, and 2023) to determine what the research focussed on. There were a total of 572 project grants abstracts that were female-specific out of all 9731 project grant abstracts (5.87%). These female-specific grant abstracts received 0.64% of total CIHR funding awarded to project/operating grants over the 13 years ($358,152,226 out of $55,725,229,388 in total CIHR funding). We next examined what percentage of female-specific grants mentioned investigating one of the top 11 global burdens of disease and death identified for women: low back pain, depressive disorders, headache disorders, anxiety, musculoskeletal disorders, Alzheimer's disease and other dementias, HIV/AIDS CVDs, cancer, diabetes, and respiratory diseases (Patwardhan et al., 2024; Peters et al., 2016).

Aside from cancer, over 13 years female-specific project grant abstracts that mentioned the top 10 global burdens of disease and death for women accounted for approximately 2% of all funded CIHR project grant abstracts

Surprisingly, out of all 572 female-specific grant abstracts spanning 13 years, none mentioned low back pain, one mentioned headache disorders, eight mentioned AD and other dementias, and eight mentioned respiratory diseases (Figure 3A). The leading cause of global disease burden mentioned in female-specific grant abstracts was cancer, making up 35.14% of female-specific grant abstracts and 2.07% of all funded CIHR grant abstracts over the 13 years (201 of 9731). However, aside from cancer, the 10 other areas of global disease burden received low research representation. Collectively, female-specific grants that mentioned low back pain, depressive disorders, headache disorders, anxiety, musculoskeletal disorders, Alzheimer's disease and other dementias, and HIV/AIDS, CVDs, respiratory diseases, and diabetes accounted for 37.76% of female-specific grant abstracts (Figure 3A). In other words, these 10 areas of

global disease burden *combined* accounted for 2.21% of all funded CIHR grant abstracts over the 13 years analyzed (216 of 9731; Figure 3A) and received approximately the same amount of research representation as cancer.


A
REPRESENTATION
Female-Specific Grant Abstracts by Cause of Global Disease Burden
Cancer 201 (35.14%)
CVDs 78 (13.64%)
HIV/AIDS 39 (6.82%)
Diabetes 32 (5.59%)
Depressive Disorders 29 (5.07%)
Musculoskeletal Disorders 12 (2.1%)
Anxiety 12 (2.1%)
AD and Other Dementias 8 (1.4%)
Respiratory Diseases 5 (0.87%)
Headache Disorders 1 (0.17%)
Low Back Pain 0 (0%)
0 10 20 30 40
As Percentage of Female-Specific Grant Abstracts
Female-Specific Grant Abstracts by Cause of Global Disease Burden
Cancer 201 (2.07%)
CVDs 78 (0.8%)
HIV/AIDS 39 (0.4%)
Diabetes 32 (0.33%)
Depressive Disorders 29 (0.3%)
Musculoskeletal Disorders 12 (0.12%)
Anxiety 12 (0.12%)
AD and Other Dementias 8 (0.08%)
Respiratory Diseases 5 (0.05%)
Headache Disorders 1 (0.01%)
Low Back Pain 0 (0%)
0 10 20 30 40
As Percentage of All Grant Abstracts
Grant Abstracts from 2009-2020 & 2023
Female-Specific (n = 572 over 13 years)
All Grant Abstracts (n = 9731 over 13 years)


B
FUNDING
Female-Specific Grant Abstracts by Cause of Global Disease Burden
Cancer $136.76M (38.18%)
CVDs $41.13M (11.48%)
HIV/AIDS $32.61M (9.11%)
Depressive Disorders $15.76M (4.4%)
Diabetes $14.93M (4.17%)
Musculoskeletal Disorders $7.95M (2.22%)
Anxiety $7.27M (2.03%)
AD and Other Dementias $6.19M (1.73%)
Respiratory Diseases $3.44M (0.96%)
Headache Disorders $0.15M (0.04%)
Low Back Pain $0M (0%)
0 10 20 30 40
As Percentage of Female-Specific Grant Abstracts
Female-Specific Grant Abstracts by Cause of Global Disease Burden
Cancer $136.76M (2.2%)
CVDs $41.13M (0.66%)
HIV/AIDS $32.61M (0.52%)
Depressive Disorders $15.76M (0.25%)
Diabetes $14.93M (0.24%)
Musculoskeletal Disorders $7.95M (0.13%)
Anxiety $7.27M (0.12%)
AD and Other Dementias $6.19M (0.1%)
Respiratory Diseases $3.44M (0.06%)
Headache Disorders $0.15M (0.002%)
Low Back Pain $0M (0%)
0 10 20 30 40
As Percentage of All Grant Abstracts
Grant Abstracts from 2009-2020 & 2023
Female-Specific ($358.15M over 13 years)
All Grant Abstracts ($6224.48M over 13 years)

Figure 3. Breakdown of the 572 female-specific grant abstracts from 2009-2020 and 2023 according to the 11 causes of global disease burden and death that disproportionately affect females by A) research representation, and B) funding. Breakdown is provided as a proportion of female-specific grant abstracts in red and as a proportion of all grant abstracts in blue. Funding amounts are provided in millions (M). Created in https://BioRender.com.

A linear regression showed that there were significant differences in the percentage of female-specific grant abstracts by cause of global disease burden ($F(10, 132) = 94.25$, $p < 0.001$, $\eta^2 = 0.88$, 95% CI: [0.85, 1.00]). Post hoc comparisons revealed that the overall percentage of female-specific grant abstracts mentioning cancer was significantly greater than all other causes of global disease burden (for all contrasts with cancer: $t(132) = 14.63$ to 23.87, $p < 0.0001$, Cohen's $d = 5.74$ to 9.36, see Supplementary Table 1 for all pairwise comparisons). Those mentioning CVDs were also significantly greater than all other causes of global disease burden except cancer (Supplementary Table 1). Additionally, the overall percentage of grant abstracts mentioning low back pain and headache disorders was significantly less than HIV/AIDS, depressive disorders, CVDs, and diabetes (Supplementary Table 1). The overall percentage of grant abstracts mentioning AD and other dementias was significantly less than HIV/AIDS (Supplementary Table 1).

Interestingly, the majority of female-specific grant abstracts that mentioned depressive disorders were dedicated to depressive disorders in pregnancy and postpartum (58.62%; 17 of 29); this is 8.5 times the percentage of grant abstracted dedicated to depressive disorders in perimenopause and menopause (6.90%; 2 of 29). None of the 572 funded female-specific grant abstracts mentioned premenstrual dysphoric disorder (PMDD, 0%) or mentioned studying the relationship between the menstrual cycle and depressive disorders. Similarly, the majority of female-specific grant abstracts that mentioned CVDs were dedicated to CVDs in pregnancy and postpartum (62.82%; 49 of 78); this is 49 times the percentage of grant abstracts dedicated to CVDs in perimenopause and menopause (1.28%; 1 of 78).

Out of the 201 grant female-specific abstracts that mentioned any type of cancer, the overwhelming majority covered breast (53.9%) and gynecologic (35.84%) cancers (i.e., cervical, endometrial, ovarian, uterine, or vulvar). The remaining 10.18% covered colorectal, thyroid, throat, skin, liver, oral, ocular, and pancreatic cancers, however, all of these were in combination with breast or gynecologic cancer. In other words, all female-specific grants spanning the 13

years investigating cancer included breast and/or gynecologic cancers as part of their research focus.

Cancer received a significantly greater percentage of funding than the other 10 causes of global disease burden that disproportionately affect females. CVDs and HIV/AIDs also received a significantly greater percentage of funding than most other causes of global disease burden.

A linear regression showed that there were significant differences in the percentage of female-specific funding awarded to grant abstracts by cause of global disease burden ($F(10, 132) = 89.72$, $p < 0.0001$, $\eta^2 = 0.87$, 95% CI: [0.84, 1.00]; Figure 3B). Post hoc Tukey-adjusted comparisons revealed that the overall percentage of female-specific funding awarded to grant abstracts mentioning cancer was significantly greater than those mentioning the 10 other causes of global disease burden (for all contrasts with cancer: $t(132) = 16.13$ to 23.09, $p < 0.0001$, Cohen's $d = 6.32$ to 9.06, see Supplementary Table 2 for all pairwise comparisons). The percentage of female-specific funding awarded to grant abstracts mentioning CVDs was significantly greater than all other causes of global disease burden except HIV/AIDS and cancer (Supplementary Table 2). Additionally, female-specific funding awarded to grant abstracts mentioning HIV/AIDS was significantly greater than all other causes of global disease burden except cancer, CVDs, depressive disorders, and diabetes (Supplementary Table 2).

Causes of global disease burden that disproportionately affect females did not show significant changes in representation or funding percentages over time

Linear regressions revealed that the percentage of female-specific grant abstracts mentioning anxiety, depressive disorders, musculoskeletal disorders, Alzheimer's disease and other dementias, HIV/AIDS, headache disorders, CVDs, respiratory diseases, diabetes, or cancer did not show significant changes over time, and the percentage of funding dedicated to these causes of global disease burden also did not significantly change over time (Figure 4; see Supplementary Table 3 for statistics, adjusted $p \geq 0.28$ for all models).



Figure 4. Breakdown of the 572 female-specific grant abstracts over time from 2009-2020 and 2023 according to the 11 causes of global disease burden and death that disproportionately affect females. Breakdown is provided as a proportion of female-specific grant abstracts in red and as a proportion of all grant abstracts in blue. Research representation is represented by circles and research funding is represented by triangles. The amount of research representation and funding did not significantly change over time for any of the causes.

Discussion

Overall, our analysis of CIHR project grant abstracts revealed that the percentage of abstracts mentioning sex, gender and 2S/LGBTQ+ doubled or quadrupled from 2020 to 2023. However, despite these gains, the percentages of abstracts mentioning sex, gender or 2S/LGBTQ+ remained at under 10% of overall funded abstracts. In contrast, progress for female-specific research representation remained unchanged from 2020 to 2023 at ~7% . Furthermore, the majority of female-specific project grants funded across 13 years of funding from CIHR were focused on breast and gynecological cancers or pregnancy, with disproportionately more funding going to cancer research. Cancer research that focused only on females, which represented 2.07% of total grant abstracts, received significantly more representation and funding than all other causes of global disease burden and death that disproportionately affect females. In fact, grant abstracts mentioning the other top 10 causes of global disease burden and death *combined* had a similar amount of research representation and funding as cancer research. Indeed, in terms of female-specific project grant abstracts, only 2.21% of total grant abstracts mentioning the top 10 global burden of disease for women were funded when cancers were excluded. Females are 50% of the worldwide population, and 50.7% in Canada (S. C. Government of Canada, 2022), and given the more time spent in chronic illness than males (*Closing the Women's Health Gap to Improve Lives and Economies*, n.d.), it underscores the urgent need for more funding for women's health research in other areas of research. Furthermore, no significant increases in funding or research representation dedicated to any of these causes of top causes of disease or death for women were observed over the 13 years. Collectively, our findings suggest that more efforts beyond SGBA+ mandates are needed to increase female-specific research and funding.

Funded Grant abstracts mentioning studying sex, gender or 2S/LGBTQ populations doubled or quadrupled from 2020 to 2023, but remain under 10% of grants funded

Progress was seen from 2020 to 2023 in grant abstracts mentioning studying sex, gender, or 2S/LGBTQ+, but overall increases were small in magnitude. Given that the SGBA has been mandatory since 2019, it still remains under disclosed in the public abstracts. This matches surveys of published literature which demonstrates that ~5%-20% of findings, depending on the

discipline, analyse with sex/gender as a meaningful variable, rather than using it as a confounder or covariate in the analyses (Duffy & Epperson, 2022; Garcia-Sifuentes & Maney, 2021; Rechlin et al., 2022). Reviewers and funding agencies must recognize that there are several types of sex differences beyond more obvious differences in prevalence and risk as diseases can manifest differently between males and females (Lee et al., 2024). They can be *mechanistic* in nature, such that the cellular machinery underlying a given trait can be different between sexes. They can also be *latent*, such that a sex difference can emerge with a certain condition, stressor, or environment (e.g., age, genotype, disease). For example, males and females show similar levels of CSF tau-pathology if they carry the apolipoprotein (APOE) ε3 or ε2 genotype, but females show significantly higher levels than males if they carry the APOE ε4 genotype - the greatest genetic risk factor for sporadic Alzheimer's disease (AD) (Duarte-Guterman et al., 2021). Improved education of these types of "hidden" sex differences is important to dispel the myth that female health should solely focus on female reproductive organs, and will aid the development of effective, individualized therapeutics.

Relatedly, SGBA+ requires a more thorough investigation *within* a sex/gender group - especially groups who have historically been underrepresented, undervalued, and underfunded. Migraines, one type of headache disorder, are related to ovarian hormone fluctuations (Krause et al., 2021). For some, hormonal contraceptives - which are used by approximately 300 million people worldwide (United Nations, 2019) - may exacerbate migraines, and for others it may lead to improvements (Afridi, 2020). Similar mixed findings have been observed with menopausal hormone therapy effects on cognition and dementia risk (Gravelsins & Galea, in press). We must understand why these seemingly mixed findings exist to develop precision treatments. Likewise, sex- and gender-specific health knowledge is needed to develop sex-specific norms and diagnostics. In fact, when sex-specific norms are used to diagnose amnestic mild cognitive impairment - a prodromal state to AD - diagnostic accuracy is improved by 20% (Sundermann et al., 2019, 2021). Sexual and gender minority groups are more likely to receive delayed breast cancer diagnoses compared to heterosexual women and are 3 times as likely to experience breast cancer recurrence (Eckhert et al., 2023; Kluitenberg Harris et al., 2025). These delays in diagnosis and increased rates of recurrence partly stem from a lack of research specific to these groups. Even within 2S/LGBTQ+ grant abstracts, we found that double the number of abstracts focused on sexually-/gender-diverse men compared to sexually-/gender-diverse women,

suggesting that even within gender diverse populations and with sexual orientation research, more research is focused on males. Thus, health knowledge from male only research cannot be generalized to other groups, and inadequate research representation drives gaps in health knowledge and disparities in health outcomes.

No improvements in the percentage or amount of funded Women's Health Research across years.

Examining what female-specific research was funded across 572 grant abstracts across 13 years, revealed that cancer received significantly more research representation and funding and all funded cancer-related female-specific project grants included breast and gynecologic cancers. In fact, only 10.18% of cancer-related female-specific project grants additionally included another type of cancer (e.g., colorectal, thyroid, pancreatic). Cancer is one of the top global burdens of disease for women, and breast and gynecological cancers account for approximately 36.4% of cancers in women in Canada (*Canadian Cancer Statistics Dashboard (CCSD) (Incidence)*, n.d.) making it an imperative to research this area. However, there are 10 other global burdens of disease that rank higher than cancer for women. In addition, women spend 25% more time in ill health than men; more research dedicated to women is required to determine at what points in the lifespan these discrepancies emerge to identify periods of heightened vulnerability for initiating targeted treatments. Women differ from men, not only in terms of female-only disorders that uniquely impact women (ovarian cancer, endometriosis), but also women are disproportionately more likely to be diagnosed with certain diseases (autoimmune, AD, anxiety, PTSD, depression) and women present with certain disorders with a different constellation of symptoms, and/or different underlying mechanisms (heart attack, stroke) (*Women at the Forefront of Aging in Canada. 2024 Report*, n.d.). Therefore, research dedicated to conditions that *equally* affect the sexes - but investigate sex-specific mechanisms and interactions with age and genotype - are also necessary.

Thus, our analysis revealed that the breadth of female-specific research is narrow. When we examined the global burdens of disease and death that disproportionately affect females, we found biases in what type of female-specific research was being funded. Cancer, which accounted for 2.07% of all CIHR abstracts over 13 years, received approximately the same

amount of research representation as the 10 other global burdens of disease and death *combined*. Collectively, only 2.21% of all CIHR abstracts over 13 years focused on low back pain, depressive disorders, headache disorders, anxiety, musculoskeletal disorders, Alzheimer's disease and other dementias, and HIV/AIDS, Cardiovascular diseases (CVDs), respiratory diseases, and diabetes combined.

Even in funded grant abstracts dedicated to CVDs and depressive disorders, it was clear that only a certain female population was being tested, with significantly more focus on pregnancy than any other time period, including menopause. The loss of ovarian hormones related to menopause is an inflection point in the aging process for females, which can set a trajectory for health depending on menopause type, hormone therapy treatment, genetics, and social factors (Gravelsins & Galea, in press). Furthermore all females will undergo menopause, but not all undergo pregnancy, making it all the more imperative to stimulate more research on menopause. Early menopause and surgically induced menopause increase risk for AD and other dementias (Karamitrou et al., 2023). Moreover, with a growing aging population, research dedicated to AD, dementia, and other neurodegenerative diseases is crucial. However, we found that only *eight* funded female-specific grants mentioned AD and other dementias over the 13 years. This is especially surprising, as females make up two-thirds of individuals with AD and experience greater AD pathology, faster cognitive decline, and greater AD lifetime risk compared to males (Duarte-Guterman et al., 2021; Irvine et al., 2012). By 2050, the global number of dementia cases is estimated to be at 153 million, and the number of younger individuals with dementia is growing. A 122.33% increase in dementia prevalence was noted in individuals less than 70 years of age group from 1990 to 2021 (Li et al., 2024). In Canada alone, dementia costs were estimated at $40.1 billion in 2020 (Canadian Centre for Economic Analysis, 2023). A lack of female-specific research in this area contributes to ineffective treatments. Lecanemab, the recently FDA-approved drug for AD, is significantly less effective in females (Dyck et al., 2023). Recent studies indicate targeting immune challenges may be more effective in females compared to males to reduce the risk of AD (Eyting et al., 2025; Lopez-Lee et al., 2021). With growing dementia burden, especially for females at a younger age, early interventions that incorporate female-specific factors into their investigations are key for achieving precision medicine.

Another area of importance is mental health. There are growing rates of mental health concerns (Arias et al., 2022), there are sex differences in mental health incidence, prevalence, diagnosis, and treatments, and several mental health conditions favouring females (e.g., depression, anxiety, and panic disorders) emerge during puberty, are related to menstrual cycles, and can manifest differently throughout the lifespan (Paus et al., 2008). Thus, different etiologies and different drug targets may be needed to combat mental health conditions depending on sex. Major depressive disorder (MDD) is two to three times more prevalent in females compared to males, shows different, often opposing biomarkers and transcriptional profiles (Labonté et al., 2017; Moieni et al., 2015; Seney et al., 2018). Given these sex differences, perhaps it is not so surprising that a recent phase 3 clinical trial of Navacaprant, a selective kappa opiate antagonist, found a significant improvement in females with MDD but not in males with MDD (*Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder | Neumora Therapeutics, Inc.*, n.d.). These findings, collectively, suggest that more research is warranted to uncover why there are different signatures of MDD in females than males. However, given that 20% of the population will experience depression or anxiety across their lifespan only 0.37% of funded grants were on female-specific studies in anxiety and depression, suggesting a large gap in needed research. Furthermore, these conditions were largely studied in the context of pregnancy. In fact, none of the 572 funded female-specific grant abstracts over 13 years mentioned premenstrual dysphoric disorder, or the relationship between the menstrual cycle and depressive disorders. Given the potential link of mental health conditions, including anxiety and depression, to ovarian hormones, there is a need to investigate the influence of various hormonal transitions across the lifespan on the brain. In addition to pregnancy, mental health research must consider puberty, menstrual cycles, hormonal contraception, emergency contraception, postpartum, and menopause. Taking a lifespan approach is necessary to lessen the 25% increased amount of time that women spend in poor health compared to men.

Strengths and Weaknesses

A major strength of our study is the longitudinal analysis, which was conducted using data from 13 years of CIHR abstracts. This longitudinal approach provided valuable insights into trends in research representation and funding over time. Moreover, a detailed thematic analysis

of the female-specific grant abstracts provided further insight into their content, and revealed striking biases in the focus of the grant abstracts; it revealed a significant emphasis on pregnancy research compared to any other time point in a female's lifespan. Additionally, the public availability of the CIHR grant abstracts used in our analyses provides researchers and funding agencies alike with transparency and accessibility to the data underlying our analysis.

One limitation is that we were restricted to publicly available data, which is currently confined to the public abstract, which has word constraints and not the detail seen in the scientific summaries. Thus, it is possible research integrating SGBA+ , specific populations of interest, or diseases/conditions of interest were missed due to omissions of details and analysis plans. However, our bar for categorization was low, such that if an abstract simply mentioned the population/disease/condition of interest, it was sufficient to be categorized as such. Relatedly, because only public abstracts were analyzed, we were unable to assess if optimal statistical analyses were appropriately selected to meaningfully uncover sex or gender differences, e.g., avoiding sex or gender as covariates, and avoiding using matched samples. In an in depth analysis of published psychiatry and neuroscience research articles, optimal statistical analyses are often not selected (Rechlin et al., 2022), which is similar to findings across multiple disciplines (Garcia-Sifuentes & Maney, 2021; Kilpatrick et al., 2023) Additionally, the sex of the nominated principal investigators of female-specific project grant abstracts was inferred based on their first names. We recognize that this approach has limitations, as sex may not align with gender identity, and the perceived masculinity or femininity of a name may not reflect an individual's sex.

Although not the focus of our study, it is also possible that males are ignored in research for diseases and conditions that affect all sexes, but are more prevalent in females. We observed that out of the 26 project grants from 2023 that focused on breast cancer, none focused exclusively on breast cancer in males. Autoimmune conditions, osteoporosis, anxiety and depression disproportionately affect females, but still influence males and intersex individuals. We recognize that research on these diseases and conditions in non-female populations is also important, and is an area that should be explored in future research. However, recognizing that female-specific research continues to be undervalued - especially in the top causes of global

disease burden and death - suggests that efforts beyond SGBA+ mandates are needed to increase female-specific research and funding.

A path forward: Recommendations beyond mandates

Our analysis suggests that more SGBA+ efforts, beyond mandates, are necessary to increase research on sex, gender, 2S/LGBTQ+, and most notably female-specific research - the only area of our analysis that did not show changes in research representation from 2020 to 2023. Females make up approximately 50% of the population, yet research pertaining to females received only 7% of all CIHR project grant research representation and funding. Even within 2A/LGBTQ+ funded abstracts, there were more grants that focussed on men than women (Namchuk et al., 2025).

Dedicated research funding is a cornerstone of women's health progress and knowledge generation. As demonstrated by financial investment in and prioritizing of antiretroviral therapy research, Human Immunodeficiency Virus (HIV) burden significantly reduced, making it a livable condition rather than a fatal disease (Broder, 2010). Research progress and knowledge generation stems from dedicated research funding, underscoring the importance of dedicated and protected women's health research funding. The Canadian Heart and Stroke Foundation Women's Research Network, which funds research to advance understanding of women's unique risk factors for heart disease and stroke (Heart and Stroke Foundation of Canada, n.d.) and The Cutting Alzheimer's Risk through Endocrinology (CARE) grant ("CARE Program Details," n.d.), which funds AD-related women's health research with the goal of halving the lifetime AD risk among women, are steps in the right direction to closing the women's health gap. However, more protected funding is needed, especially for the 11 causes of disease burden and death that disproportionately affect females. This includes funding for headache disorders, which disproportionately affect women and approximately 40% of the human population (*Migraine and Other Headache Disorders*, n.d.), but was only mentioned in *one* female-specific funded grant abstract over 13 years, and low back pain, which disproportionately affects women and approximately 619 million people globally (*Low Back Pain*, n.d.), but was not mentioned in any female-specific funded grant abstract over 13 years. These alarming statistics reinforce that women's health continues to be significantly underfunded. Having protected women's health

research funding, within federal agencies, provides assurances that female health will be researched..

It is not clear why SGBA has not led to an increase in women's health research funding but it may be related to a lack of opportunities for women researchers and women's research topics. Having more women's health special issues in renowned health, neuroscience, and psychiatry journals is critical to closing the women's health gap. These special issues reinforce the value of women's health research and provide an opportunity to further women's health knowledge in areas beyond reproductive health. The Journal of the American Medical Association (JAMA) International Medicine series "Improving Women's Health Across the Life Span" was introduced in 2024 to increase published articles relating to women's health (Grady et al., 2024). Notably, this JAMA women's health series also includes distinguished women's health reviewers, which is vital for increasing rigorous women's health research. Less than one-third of peer reviewers for medical journals are women (Pinho-Gomes et al., 2022). Having women reviewers and editors has been shown to positively correlate with the more published research from women's first and last authors (Last et al., 2022), and women are more likely to publish on women's health (Rechlin et al., 2022). Beyond these women's health special issues, having an editorial board consisting of SGBA+ champions to advocate for rigorous women's health research is a must. Currently, the CIHR does not have a dedicated review panel for women's health research. Our analysis suggests that this should be revisited.

Lastly, for SGBA+ accountability, we recommend engaging persons with lived experience and forming an advisory committee of SGBA+ experts who weigh in at every stage of the research process (design, recruitment, analysis, reporting, and knowledge translation). Additionally, SGBA+ requires the integration of intersectional factors, like ethnicity, physical ability, age, and genetics. Embracing this complexity in research is a must to achieve precision medicine - effective, individualized treatments - which can only be accomplished with sufficient research representation and funding.

Conclusions

We must move beyond sex and gender mandates to close the women's health gap. Even with CIHR SGBA mandates in place, female health research did not increase over time and continues to be significantly lacking in areas outside of reproductive health as well as toward the

top female causes of global disease burden and death. These gaps are even greater for marginalized groups, including women of colour and women with disabilities (Hankivsky et al., 2010; Homan et al., 2021). Dedicated, protected research funding for women's health and women's health special issues in top health journals is essential to diversify female-specific research and advance basic science centered on women. Additionally, more women and experts who understand women's health are needed in leadership positions to ensure rigorous women's health research is prioritized. Critically, researching women's health factors will have significant economic benefits and will improve personalized medicine and health outcomes for everyone, not just women. Studying heart attack symptoms in females continues to help refine diagnostic criteria and potential treatments for both males and females (Alraies & Piña, 2019), and in 2019 the Canadian Cardiovascular Society endorsed the inclusion of sex and gender in guideline developments (Sjaus & Fakhory, 2025). Ambien remains one of the few FDA approved drugs with sex-specific dosing (Zhao et al., 2023). Females require half the dose as males for effective sleep maintenance due to slower drug metabolism. Using lower doses has helped reduce excessive morning sleepiness and Ambien-associated cognitive impairment in females (Yoon et al., 2021), with important implications for workplace safety and impaired driving accidents. These examples are a reminder that we must continue to advocate for women's health to break the cycle of underfunding, undervaluing, and underrepresenting women's health in research.

Funding This work was supported by womenmind™ to LAMG (CAMHF-1197), and a contribution from the Government of Canada's New Frontiers in Research Fund (grant number NFRF-T-2022-00051). We also gratefully acknowledge funding from the Women's Health Research Cluster to LLG, and AM.

References

Afridi, S. K. (2020). Migraine: Navigating the hormonal minefield. *Practical Neurology*, *20*(2), 115–121. https://doi.org/10.1136/practneurol-2019-002332

Alraies, M. C., & Piña, I. L. (2019). Closing the Gap on Sex Disparity in Acute Coronary Syndrome: Is It Time to Reconsider Our Definitions of “Typical”? *Journal of the American Heart Association*, *8*(17), e013739. https://doi.org/10.1161/JAHA.119.013739

Arias, D., Saxena, S., & Verguet, S. (2022). Quantifying the global burden of mental disorders and their economic value. *eClinicalMedicine*, *54*, 101675. https://doi.org/10.1016/j.eclinm.2022.101675

Blokland, G. A. M., Grove, J., Chen, C.-Y., Cotsapas, C., Tobet, S., Handa, R., Schizophrenia Working Group of the Psychiatric Genomics Consortium, St Clair, D., Lencz, T., Mowry, B. J., Periyasamy, S., Cairns, M. J., Tooney, P. A., Wu, J. Q., Kelly, B., Kirov, G., Sullivan, P. F., Corvin, A., Riley, B. P., … Goldstein, J. M. (2022). Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders. *Biological Psychiatry*, *91*(1), 102–117. https://doi.org/10.1016/j.biopsych.2021.02.972

Broder, S. (2010). The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. *Antiviral Research*, *85*(1), 1–18. https://doi.org/10.1016/j.antiviral.2009.10.002

Cahill, L. (2018). How does hormonal contraception affect the developing human adolescent brain? *Current Opinion in Behavioral Sciences*, *23*, 131–135. https://doi.org/10.1016/j.cobeha.2018.06.015

Canadian Cancer Statistics Dashboard (CCSD) (Incidence). (n.d.). Retrieved April 7, 2025, from http://cancerstats.ca/Login/Index

CARE Program Details. (n.d.). *Wellcome Leap: Unconventional Projects. Funded at Scale.* Retrieved April 14, 2025, from https://wellcomeleap.org/care/

Closing the Women’s Health Gap to Improve Lives and Economies. (n.d.). World Economic

Forum. Retrieved March 4, 2025, from https://www.weforum.org/publications/closing-the-women-s-health-gap-a-1-trillion-opportunity-to-improve-lives-and-economies/

Cooke, R. R., McIntosh, J. E. A., & McIntosh, R. P. (1993). Circadian variation in serum free and non-SHBG-bound testosterone in normal men: Measurements, and simulation using a mass action model. *Clinical Endocrinology*, *39*(2), 163–171. https://doi.org/10.1111/j.1365-2265.1993.tb01769.x

Duarte-Guterman, P., Albert, A. Y., Barha, C. K., Galea, L. A. M., & On Behalf Of The Alzheimer's Disease Neuroimaging Initiative, null. (2021). Sex influences the effects of APOE genotype and Alzheimer's diagnosis on neuropathology and memory. *Psychoneuroendocrinology*, *129*, 105248. https://doi.org/10.1016/j.psyneuen.2021.105248

Duffy, K. A., & Epperson, C. N. (2022). Evaluating the evidence for sex differences: A scoping review of human neuroimaging in psychopharmacology research. *Neuropsychopharmacology*, *47*(2), 430–443. https://doi.org/10.1038/s41386-021-01162-8

Dyck, C. H. van, Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., Froelich, L., Katayama, S., Sabbagh, M., Vellas, B., Watson, D., Dhadda, S., Irizarry, M., Kramer, L. D., & Iwatsubo, T. (2023). Lecanemab in Early Alzheimer's Disease. *New England Journal of Medicine*, *388*(1), 9–21. https://doi.org/10.1056/NEJMoa2212948

Eckhert, E., Lansinger, O., Ritter, V., Liu, M., Han, S., Schapira, L., John, E. M., Gomez, S., Sledge, G., & Kurian, A. W. (2023). Breast Cancer Diagnosis, Treatment, and Outcomes of Patients From Sex and Gender Minority Groups. *JAMA Oncology*, *9*(4), 473–480. https://doi.org/10.1001/jamaoncol.2022.7146

Eyting, M., Xie, M., Michalik, F., Heß, S., Chung, S., & Geldsetzer, P. (2025). A natural experiment on the effect of herpes zoster vaccination on dementia. *Nature*, 1–9.

https://doi.org/10.1038/s41586-025-08800-x

Fejzo, M., Rocha, N., Cimino, I., Lockhart, S. M., Petry, C. J., Kay, R. G., Burling, K., Barker, P., George, A. L., Yasara, N., Premawardhena, A., Gong, S., Cook, E., Rimmington, D., Rainbow, K., Withers, D. J., Cortessis, V., Mullin, P. M., MacGibbon, K. W., … O'Rahilly, S. (2024). GDF15 linked to maternal risk of nausea and vomiting during pregnancy. *Nature*, *625*(7996), 760–767. https://doi.org/10.1038/s41586-023-06921-9

Fisk, N., & Atun, R. (2009). Systematic analysis of research underfunding in maternal and perinatal health. *BJOG: An International Journal of Obstetrics & Gynaecology*, *116*(3), 347–356. https://doi.org/10.1111/j.1471-0528.2008.02027.x

Galea, L. A. M., Lee, B. H., de leon, R. G., Rajah, M. N., & Einstein, G. (2023). Chapter 45 - Beyond sex and gender differences: The case for women's health research. In M. J. Legato (Ed.), *Principles of Gender-Specific Medicine (Fourth Edition)* (pp. 699–711). Academic Press. https://doi.org/10.1016/B978-0-323-88534-8.00045-6

Garcia-Sifuentes, Y., & Maney, D. L. (2021). Reporting and misreporting of sex differences in the biological sciences. *eLife*, *10*, e70817. https://doi.org/10.7554/eLife.70817

Gonçalves, B. M. M., Franco, R. P. V., & Rodrigues, A. S. (2021). Maternal mortality associated with COVID-19 in Brazil in 2020 and 2021: Comparison with non-pregnant women and men. *PLOS ONE*, *16*(12), e0261492. https://doi.org/10.1371/journal.pone.0261492

Government of Canada, C. I. of H. R. (2008, November 20). *Funding Decisions Database*. https://webapps.cihr-irsc.gc.ca/decisions/p/main.html?lang=en#sort=namesort%20asc&start=0&rows=20.

Government of Canada, S. C. (2022, February 9). *Profile table, Census Profile, 2021 Census of Population—Canada [Country]*. https://www12.statcan.gc.ca/census-recensement/2021/dp-pd/prof/index.cfm?Lang=E

Grady, D., Allore, H. G., Corbie, G., Covinsky, K. E., Durant, R. W., Ganguli, I., Gross, C. P., Katz, M. H., Mody, L., Wang, T., Tripodis, Y., & Inouye, S. K. (2024). Improving

Women's Health Across the Life Span—JAMA Internal Medicine Call for Papers. *JAMA Internal Medicine*, *184*(5), 472–473. https://doi.org/10.1001/jamainternmed.2024.0136

Gravelsins, L. L., & Galea, L. A. M. (in press). *One size does not fit all: How type of menopause and hormone therapy matters for brain health*.

Hallam, L., Vassallo, A., Pinho-Gomes, A.-C., Carcel, C., & Woodward, M. (2022). Does Journal Content in the Field of Women's Health Represent Women's Burden of Disease? A Review of Publications in 2010 and 2020. *Journal of Women's Health*, *31*(5), 611–619. https://doi.org/10.1089/jwh.2021.0425

Hankivsky, O., Reid, C., Cormier, R., Varcoe, C., Clark, N., Benoit, C., & Brotman, S. (2010). Exploring the promises of intersectionality for advancing women's health research. *International Journal for Equity in Health*, *9*(1), 5. https://doi.org/10.1186/1475-9276-9-5

Heart and Stroke Foundation of Canada. (n.d.). *What we don't know is hurting women*. Heart and Stroke Foundation of Canada. Retrieved April 14, 2025, from https://www.heartandstroke.ca/en/women/

Homan, P., Brown, T. H., & King, B. (2021). Structural Intersectionality as a New Direction for Health Disparities Research. *Journal of Health and Social Behavior*, *62*(3), 350–370. https://doi.org/10.1177/00221465211032947

Irvine, K., Laws, K. R., Gale, T. M., & Kondel, T. K. (2012). Greater cognitive deterioration in women than men with Alzheimer's disease: A meta analysis. *Journal of Clinical and Experimental Neuropsychology*, *34*(9), 989–998. https://doi.org/10.1080/13803395.2012.712676

Karamitrou, E. K., Anagnostis, P., Vaitsi, K., Athanasiadis, L., & Goulis, D. G. (2023). Early menopause and premature ovarian insufficiency are associated with increased risk of dementia: A systematic review and meta-analysis of observational studies. *Maturitas*, *176*, 107792. https://doi.org/10.1016/j.maturitas.2023.107792

Kilpatrick, L. A., An, H. M., Pawar, S., Sood, R., & Gupta, A. (2023). Neuroimaging

Investigations of Obesity: A Review of the Treatment of Sex from 2010. *Current Obesity Reports*, *12*(2), 163–174. https://doi.org/10.1007/s13679-023-00498-0

Kluitenberg Harris, C., Wu, H.-S., Lehto, R., Wyatt, G., & Given, B. (2025). Relationships Among Determinants of Health, Cancer Screening Participation, and Sexual Minority Identity: A Systematic Review. *LGBT Health*, *12*(1), 3–19. https://doi.org/10.1089/lgbt.2023.0097

Koch, A. R., Craemer, K. A., Garland, C. E., Fox, W. B., Jones, C. T., Qualls, A. C., Sterr, J. C., & Geller, S. E. (2024). Federally Funded Randomized Controlled Trials Increase Analysis and Reporting of Study Outcomes by Sex, Race, and Ethnicity. *Journal of Women's Health (2002)*, *33*(1), 14–19. https://doi.org/10.1089/jwh.2023.0307

Krause, D. N., Warfvinge, K., Haanes, K. A., & Edvinsson, L. (2021). Hormonal influences in migraine—Interactions of oestrogen, oxytocin and CGRP. *Nature Reviews Neurology*, *17*(10), 621–633. https://doi.org/10.1038/s41582-021-00544-2

Labonté, B., Engmann, O., Purushothaman, I., Menard, C., Wang, J., Tan, C., Scarpa, J. R., Moy, G., Loh, Y.-H. E., Cahill, M., Lorsch, Z. S., Hamilton, P. J., Calipari, E. S., Hodes, G. E., Issler, O., Kronman, H., Pfau, M., Obradovic, A. L. J., Dong, Y., … Nestler, E. J. (2017). Sex-specific transcriptional signatures in human depression. *Nature Medicine*, *23*(9), 1102–1111. https://doi.org/10.1038/nm.4386

Last, K., Hübsch, L., Cevik, M., Wolkewitz, M., Müller, S. E., Huttner, A., & Papan, C. (2022). Association between women's authorship and women's editorship in infectious diseases journals: A cross-sectional study. *The Lancet Infectious Diseases*, *22*(10), 1455–1464. https://doi.org/10.1016/S1473-3099(22)00367-X

Lee, B. H., Eid, R. S., Hodges, T. E., Barth, C., & Galea, L. A. M. (2024). Leveraging research into sex differences and steroid hormones to improve brain health. *Nature Reviews Endocrinology*, 1–16. https://doi.org/10.1038/s41574-024-01061-0

Li, Z., Yang, Y., Liu, Y., Wang, X., Ping, F., Xu, L., Zhang, H., Li, W., & Li, Y. (2024). Global

burden of dementia in younger people: An analysis of data from the 2021 Global Burden of Disease Study. *eClinicalMedicine*, *77*. https://doi.org/10.1016/j.eclinm.2024.102868

Lopez-Lee, C., Kodama, L., & Gan, L. (2021). Sex differences in neurodegeneration: The role of the immune system in humans. *Biological Psychiatry*, S0006-3223(21)00039-1. https://doi.org/10.1016/j.biopsych.2021.01.002

Low back pain. (n.d.). Retrieved April 14, 2025, from https://www.who.int/news-room/fact-sheets/detail/low-back-pain

Maan, A. A., Eales, J., Akbarov, A., Rowland, J., Xu, X., Jobling, M. A., Charchar, F. J., & Tomaszewski, M. (2017). The Y chromosome: A blueprint for men's health? *European Journal of Human Genetics*, *25*(11), 1181–1188. https://doi.org/10.1038/ejhg.2017.128

Mersha, T. B., Martin, L. J., Biagini Myers, J. M., Kovacic, M. B., He, H., Lindsey, M., Sivaprasad, U., Chen, W., & Khurana Hershey, G. K. (2015). Genomic architecture of asthma differs by sex. *Genomics*, *106*(1), 15–22. https://doi.org/10.1016/j.ygeno.2015.03.003

Migraine and other headache disorders. (n.d.). Retrieved April 14, 2025, from https://www.who.int/news-room/fact-sheets/detail/headache-disorders

Mirin, A. A. (2021). Gender Disparity in the Funding of Diseases by the U.S. National Institutes of Health. *Journal of Women's Health (2002)*, *30*(7), 956–963. https://doi.org/10.1089/jwh.2020.8682

Moieni, M., Irwin, M. R., Jevtic, I., Olmstead, R., Breen, E. C., & Eisenberger, N. I. (2015). Sex Differences in Depressive and Socioemotional Responses to an Inflammatory Challenge: Implications for Sex Differences in Depression. *Neuropsychopharmacology*, *40*(7), 1709–1716. https://doi.org/10.1038/npp.2015.17

Namchuk, A. B., Stranges, T. N., Splinter, T. F. L., Moore, K. N., Logie, C. H., & Galea, L. A. M. (2025). Canadian Health Research Funding Patterns for Sexual and Gender Minority Populations Reflect Exclusion of Women. *LGBT Health*, *12*(2), 144–151.

https://doi.org/10.1089/lgbt.2024.0014

Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder | *Neumora Therapeutics, Inc.* (n.d.). Retrieved April 11, 2025, from https://ir.neumoratx.com/news-releases/news-release-details/neumora-therapeutics-reports-data-koastal-1-study-navacaprant/

Patwardhan, V., Gil, G. F., Arrieta, A., Cagney, J., DeGraw, E., Herbert, M. E., Khalil, M., Mullany, E. C., O'Connell, E. M., Spencer, C. N., Stein, C., Valikhanova, A., Gakidou, E., & Flor, L. S. (2024). Differences across the lifespan between females and males in the top 20 causes of disease burden globally: A systematic analysis of the Global Burden of Disease Study 2021. *The Lancet Public Health*, *9*(5), e282–e294. https://doi.org/10.1016/S2468-2667(24)00053-7

Paus, T., Keshavan, M., & Giedd, J. N. (2008). Why do many psychiatric disorders emerge during adolescence? *Nature Reviews Neuroscience*, *9*(12), 947–957. https://doi.org/10.1038/nrn2513

Peters, S. A. E., Woodward, M., Jha, V., Kennedy, S., & Norton, R. (2016). Women's health: A new global agenda. *BMJ Global Health*, *1*(3). https://doi.org/10.1136/bmjgh-2016-000080

Pinho-Gomes, A.-C., Vassallo, A., Woodward, M., & Peters, S. (2022). Cross-sectional study of the relationship between women's representation among editors and peer reviewers in journals of the British Medical Journal Publishing Group. *BMJ Open*, *12*(5), e061054. https://doi.org/10.1136/bmjopen-2022-061054

Rechlin, R. K., Splinter, T. F. L., Hodges, T. E., Albert, A. Y., & Galea, L. A. M. (2022). An analysis of neuroscience and psychiatry papers published from 2009 and 2019 outlines opportunities for increasing discovery of sex differences. *Nature Communications*, *13*(1), 2137. https://doi.org/10.1038/s41467-022-29903-3

Seney, M. L., Huo, Z., Cahill, K., French, L., Puralewski, R., Zhang, J., Logan, R. W., Tseng, G.,

Lewis, D. A., & Sibille, E. (2018). Opposite molecular signatures of depression in men and women. *Biological Psychiatry*, *84*(1), 18–27. https://doi.org/10.1016/j.biopsych.2018.01.017

Sjaus, A., & Fakhory, N. (2025). Sex and gender in perioperative cardiovascular research: Protocol for a scoping review. *Systematic Reviews*, *14*(1), 6. https://doi.org/10.1186/s13643-024-02716-9

Stranges, T. N., Namchuk, A. B., Splinter, T. F. L., Moore, K. N., & Galea, L. A. M. (2023). Are we moving the dial? Canadian health research funding trends for women's health, 2S/LGBTQ□+□health, sex, or gender considerations. *Biology of Sex Differences*, *14*(1), 40. https://doi.org/10.1186/s13293-023-00524-9

Sundermann, E. E., Barnes, L. L., Bondi, M. W., Bennett, D. A., Salmon, D. P., & Maki, P. M. (2021). Improving Detection of Amnestic Mild Cognitive Impairment with Sex-Specific Cognitive Norms. *Journal of Alzheimer's Disease: JAD*, *84*(4), 1763–1770. https://doi.org/10.3233/JAD-215260

Sundermann, E. E., Maki, P., Biegon, A., Lipton, R. B., Mielke, M. M., Machulda, M., Bondi, M. W., & Alzheimer's Disease Neuroimaging Initiative. (2019). Sex-specific norms for verbal memory tests may improve diagnostic accuracy of amnestic MCI. *Neurology*, *93*(20), e1881–e1889. https://doi.org/10.1212/WNL.0000000000008467

Tesfaye, M., Spindola, L. M., Stavrum, A.-K., Shadrin, A., Melle, I., Andreassen, O. A., & Le Hellard, S. (2024). Sex effects on DNA methylation affect discovery in epigenome-wide association study of schizophrenia. *Molecular Psychiatry*, *29*(8), 2467–2477. https://doi.org/10.1038/s41380-024-02513-9

United Nations. (2019). *Contraceptive Use by Method 2019: Data Booklet*. UN. https://doi.org/10.18356/1bd58a10-en

Walton, N., & Maguire, J. (2019). Allopregnanolone-based treatments for postpartum depression: Why/how do they work? *Neurobiology of Stress*, *11*, 100198.

https://doi.org/10.1016/j.ynstr.2019.100198

Wang, W., Min, L., Qiu, X., Wu, X., Liu, C., Ma, J., Zhang, D., & Zhu, L. (2021). Biological Function of Long Non-coding RNA (LncRNA) Xist. *Frontiers in Cell and Developmental Biology*, *9*. https://doi.org/10.3389/fcell.2021.645647

Wenger, N. K. (2021). Cardiovascular Disease in Women: Understanding the Journey. *Clinical Chemistry*, *67*(1), 24–29. https://doi.org/10.1093/clinchem/hvaa297

Westergaard, D., Moseley, P., Sørup, F. K. H., Baldi, P., & Brunak, S. (2019). Population-wide analysis of differences in disease progression patterns in men and women. *Nature Communications*, *10*(1), 666. https://doi.org/10.1038/s41467-019-08475-9

Women at the Forefront of Aging in Canada. 2024 Report. (n.d.). Academics at Women's College Hospital. Retrieved April 8, 2025, from https://www.womensacademics.ca/womens-age-lab/news-publications/wal2024report/

Yoon, S., Jeong, S., Jung, E., Kim, K. S., Jeon, I., Lee, Y., Cho, J.-Y., Oh, W.-Y., & Chung, J.-Y. (2021). Effect of CYP3A4 metabolism on sex differences in the pharmacokinetics and pharmacodynamics of zolpidem. *Scientific Reports*, *11*(1), 19150. https://doi.org/10.1038/s41598-021-98689-z

Zhao, H., DiMarco, M., Ichikawa, K., Boulicault, M., Perret, M., Jillson, K., Fair, A., DeJesus, K., & Richardson, S. S. (2023). Making a 'sex-difference fact': Ambien dosing at the interface of policy, regulation, women's health, and biology. *Social Studies of Science*, *53*(4), 475–494. https://doi.org/10.1177/03063127231168371

Zucker, I., & Prendergast, B. J. (2020). Sex differences in pharmacokinetics predict adverse drug reactions in women. *Biology of Sex Differences*, *11*(1), 32. https://doi.org/10.1186/s13293-020-00308-5

Supplementary Material

Table S1

Contrast	Estimate	*SE*	*df*	*t*-ratio	*p*-value	Cohen's *d*
Low Back Pain - Depressive Disorders	-5	1.48	132	-3.38	0.04	-1.33
Low Back Pain - Headache Disorders	-0.13	1.48	132	-0.09	1	-0.04
Low Back Pain - Anxiety	-1.94	1.48	132	-1.31	0.97	-0.51
Low Back Pain - Musculoskeletal Disorders	-1.95	1.48	132	-1.32	0.96	-0.52
Low Back Pain - AD and Other Dementias	-1.24	1.48	132	-0.84	1	-0.33
Low Back Pain - (HIV/AIDS)	-6.64	1.48	132	-4.49	0	-1.76
Low Back Pain - CVDs	-13.67	1.48	132	-9.24	0	-3.62
Low Back Pain - Respiratory Diseases	-1.34	1.48	132	-0.9	1	-0.35
Low Back Pain - Diabetes	-5.28	1.48	132	-3.57	0.02	-1.4
Low Back Pain - Cancer	-35.32	1.48	132	-23.87	0	-9.36
Depressive Disorders - Headache Disorders	4.87	1.48	132	3.29	0.048	1.29
Depressive Disorders - Anxiety	3.06	1.48	132	2.07	0.6	0.81
Depressive Disorders - Musculoskeletal Disorders	3.05	1.48	132	2.06	0.61	0.81
Depressive Disorders - AD and Other Dementias	3.76	1.48	132	2.54	0.29	1
Depressive Disorders - (HIV/AIDS)	-1.64	1.48	132	-1.11	0.99	-0.43
Depressive Disorders - CVDs	-8.67	1.48	132	-5.86	0	-2.3
Depressive Disorders - Respiratory Diseases	3.66	1.48	132	2.48	0.33	0.97
Depressive Disorders - Diabetes	-0.28	1.48	132	-0.19	1	-0.07
Depressive Disorders - Cancer	-30.31	1.48	132	-20.49	0	-8.04
Headache Disorders - Anxiety	-1.8	1.48	132	-1.22	0.98	-0.48
Headache Disorders - Musculoskeletal Disorders	-1.82	1.48	132	-1.23	0.98	-0.48
Headache Disorders - AD and Other Dementias	-1.11	1.48	132	-0.75	1	-0.29
Headache Disorders - (HIV/AIDS)	-6.51	1.48	132	-4.4	0	-1.72
Headache Disorders - CVDs	-13.54	1.48	132	-9.15	0	-3.59
Headache Disorders - Respiratory Diseases	-1.2	1.48	132	-0.81	1	-0.32
Headache Disorders - Diabetes	-5.14	1.48	132	-3.48	0.03	-1.36
Headache Disorders - Cancer	-35.18	1.48	132	-23.78	0	-9.33
Anxiety - Musculoskeletal Disorders	-0.01	1.48	132	-0.01	1	0
Anxiety - AD and Other Dementias	0.7	1.48	132	0.47	1	0.18
Anxiety - (HIV/AIDS)	-4.7	1.48	132	-3.18	0.07	-1.25
Anxiety - CVDs	-11.73	1.48	132	-7.93	0	-3.11
Anxiety - Respiratory Diseases	0.6	1.48	132	0.41	1	0.16
Anxiety - Diabetes	-3.34	1.48	132	-2.26	0.47	-0.89
Anxiety - Cancer	-33.38	1.48	132	-22.56	0	-8.85
Musculoskeletal Disorders - AD and Other Dementias	0.71	1.48	132	0.48	1	0.19
Musculoskeletal Disorders - (HIV/AIDS)	-4.69	1.48	132	-3.17	0.07	-1.24
Musculoskeletal Disorders - CVDs	-11.72	1.48	132	-7.92	0	-3.11
Musculoskeletal Disorders - Respiratory Diseases	0.61	1.48	132	0.41	1	0.16
Musculoskeletal Disorders - Diabetes	-3.33	1.48	132	-2.25	0.48	-0.88
Musculoskeletal Disorders - Cancer	-33.36	1.48	132	-22.55	0	-8.85

AD and Other Dementias - (HIV/AIDS)	-5.4	1.48	132	-3.65	0.02	-1.43
AD and Other Dementias - CVDs	-12.43	1.48	132	-8.4	0	-3.3
AD and Other Dementias - Respiratory Diseases	-0.09	1.48	132	-0.06	1	-0.03
AD and Other Dementias - Diabetes	-4.04	1.48	132	-2.73	0.2	-1.07
AD and Other Dementias - Cancer	-34.07	1.48	132	-23.03	0	-9.03
(HIV/AIDS) - CVDs	-7.03	1.48	132	-4.75	0	-1.86
(HIV/AIDS) - Respiratory Diseases	5.3	1.48	132	3.58	0.02	1.41
(HIV/AIDS) - Diabetes	1.36	1.48	132	0.92	1	0.36
(HIV/AIDS) - Cancer	-28.68	1.48	132	-19.38	0	-7.6
CVDs - Respiratory Diseases	12.33	1.48	132	8.34	0	3.27
CVDs - Diabetes	8.39	1.48	132	5.67	0	2.23
CVDs - Cancer	-21.65	1.48	132	-14.63	0	-5.74
Respiratory Diseases - Diabetes	-3.94	1.48	132	-2.66	0.23	-1.04
Respiratory Diseases - Cancer	-33.98	1.48	132	-22.97	0	-9.01
Diabetes - Cancer	-30.04	1.48	132	-20.3	0	-7.96

Table S2

Contrast	**Estimate**	***SE***	***df***	***t*-ratio**	***p*-value**	**Cohen's *d***
Low Back Pain - Depressive Disorders	-4.54	1.61	132	-2.81	0.17	-1.1
Low Back Pain - Headache Disorders	-0.03	1.61	132	-0.02	1	-0.01
Low Back Pain - Anxiety	-1.98	1.61	132	-1.23	0.98	-0.48
Low Back Pain - Musculoskeletal Disorders	-2.05	1.61	132	-1.27	0.97	-0.5
Low Back Pain - AD and Other Dementias	-1.33	1.61	132	-0.82	1	-0.32
Low Back Pain - (HIV/AIDS)	-9.04	1.61	132	-5.6	0	-2.2
Low Back Pain - CVDs	-11.24	1.61	132	-6.96	0	-2.73
Low Back Pain - Respiratory Diseases	-0.8	1.61	132	-0.5	1	-0.19
Low Back Pain - Diabetes	-4.16	1.61	132	-2.58	0.27	-1.01
Low Back Pain - Cancer	-37.28	1.61	132	-23.09	0	-9.06
Depressive Disorders - Headache Disorders	4.51	1.61	132	2.79	0.17	1.09
Depressive Disorders - Anxiety	2.55	1.61	132	1.58	0.89	0.62
Depressive Disorders - Musculoskeletal Disorders	2.49	1.61	132	1.54	0.9	0.6
Depressive Disorders - AD and Other Dementias	3.21	1.61	132	1.99	0.66	0.78
Depressive Disorders - (HIV/AIDS)	-4.5	1.61	132	-2.79	0.17	-1.09
Depressive Disorders - CVDs	-6.71	1.61	132	-4.16	0	-1.63
Depressive Disorders - Respiratory Diseases	3.74	1.61	132	2.31	0.43	0.91
Depressive Disorders - Diabetes	0.37	1.61	132	0.23	1	0.09
Depressive Disorders - Cancer	-32.74	1.61	132	-20.28	0	-7.96
Headache Disorders - Anxiety	-1.95	1.61	132	-1.21	0.98	-0.47
Headache Disorders - Musculoskeletal Disorders	-2.02	1.61	132	-1.25	0.97	-0.49
Headache Disorders - AD and Other Dementias	-1.3	1.61	132	-0.8	1	-0.32
Headache Disorders - (HIV/AIDS)	-9.01	1.61	132	-5.58	0	-2.19
Headache Disorders - CVDs	-11.21	1.61	132	-6.95	0	-2.72
Headache Disorders - Respiratory Diseases	-0.77	1.61	132	-0.48	1	-0.19
Headache Disorders - Diabetes	-4.13	1.61	132	-2.56	0.28	-1
Headache Disorders - Cancer	-37.25	1.61	132	-23.07	0	-9.05
Anxiety - Musculoskeletal Disorders	-0.07	1.61	132	-0.04	1	-0.02

Anxiety - AD and Other Dementias	0.65	1.61	132	0.4	1	0.16
Anxiety - (HIV/AIDS)	-7.06	1.61	132	-4.37	0	-1.71
Anxiety - CVDs	-9.26	1.61	132	-5.74	0	-2.25
Anxiety - Respiratory Diseases	1.18	1.61	132	0.73	1	0.29
Anxiety - Diabetes	-2.18	1.61	132	-1.35	0.96	-0.53
Anxiety - Cancer	-35.3	1.61	132	-21.87	0	-8.58
Musculoskeletal Disorders - AD and Other Dementias	0.72	1.61	132	0.45	1	0.18
Musculoskeletal Disorders - (HIV/AIDS)	-6.99	1.61	132	-4.33	0	-1.7
Musculoskeletal Disorders - CVDs	-9.19	1.61	132	-5.69	0	-2.23
Musculoskeletal Disorders - Respiratory Diseases	1.25	1.61	132	0.77	1	0.3
Musculoskeletal Disorders - Diabetes	-2.11	1.61	132	-1.31	0.97	-0.51
Musculoskeletal Disorders - Cancer	-35.23	1.61	132	-21.82	0	-8.56
AD and Other Dementias - (HIV/AIDS)	-7.71	1.61	132	-4.78	0	-1.87
AD and Other Dementias - CVDs	-9.92	1.61	132	-6.14	0	-2.41
AD and Other Dementias - Respiratory Diseases	0.53	1.61	132	0.33	1	0.13
AD and Other Dementias - Diabetes	-2.83	1.61	132	-1.75	0.8	-0.69
AD and Other Dementias - Cancer	-35.95	1.61	132	-22.27	0	-8.73
(HIV/AIDS) - CVDs	-2.21	1.61	132	-1.37	0.95	-0.54
(HIV/AIDS) - Respiratory Diseases	8.24	1.61	132	5.1	0	2
(HIV/AIDS) - Diabetes	4.88	1.61	132	3.02	0.1	1.18
(HIV/AIDS) - Cancer	-28.24	1.61	132	-17.49	0	-6.86
CVDs - Respiratory Diseases	10.44	1.61	132	6.47	0	2.54
CVDs - Diabetes	7.08	1.61	132	4.39	0	1.72
CVDs - Cancer	-26.03	1.61	132	-16.13	0	-6.33
Respiratory Diseases - Diabetes	-3.36	1.61	132	-2.08	0.59	-0.82
Respiratory Diseases - Cancer	-36.48	1.61	132	-22.6	0	-8.86
Diabetes - Cancer	-33.12	1.61	132	-20.51	0	-8.05

Table S3

Category	Term	Estimate	*SE*	*t*-statistic	*p*-value	Adjusted *p*-value	η^2
HIV/AIDS	as.numeric(year)	0.20	0.26	0.75	0.47	0.95	0.05
Anxiety	as.numeric(year)	0.10	0.14	0.70	0.50	0.95	0.04
Depression	as.numeric(year)	-0.29	0.20	-1.48	0.17	0.95	0.17
AD and Other Dementias	as.numeric(year)	0.24	0.10	2.53	0.03	0.28	0.37
Musculoskeletal Disorders	as.numeric(year)	0.05	0.15	0.36	0.72	0.95	0.01
Headache Disorders	as.numeric(year)	0.03	0.03	0.95	0.36	0.95	0.08
Respiratory Diseases	as.numeric(year)	0.08	0.13	0.61	0.56	0.95	0.03
CVDs	as.numeric(year)	0.07	0.40	0.18	0.86	0.95	0.00
Diabetes	as.numeric(year)	-0.08	0.25	-0.31	0.76	0.95	0.01
Cancer	as.numeric(year)	0.05	0.65	0.08	0.94	0.95	0.00

Depression Funding	as.numeric(year)	-0.27	0.20	-1.37	0.20	0.95	0.15
HIV/AIDS Funding	as.numeric(year)	0.31	0.36	0.85	0.41	0.95	0.06
Anxiety Funding	as.numeric(year)	0.04	0.18	0.24	0.82	0.95	0.01
AD and Other Dementias Funding	as.numeric(year)	0.28	0.11	2.64	0.02	0.28	0.39
Musculoskeletal Disorders Funding	as.numeric(year)	0.06	0.20	0.31	0.76	0.95	0.01
Headache Disorders Funding	as.numeric(year)	0.01	0.01	0.95	0.36	0.95	0.08
Respiratory Diseases Funding	as.numeric(year)	0.09	0.14	0.68	0.51	0.95	0.04
CVDs Funding	as.numeric(year)	0.14	0.32	0.43	0.67	0.95	0.02
Diabetes Funding	as.numeric(year)	-0.08	0.26	-0.32	0.75	0.95	0.01
Cancer Funding	as.numeric(year)	0.05	0.71	0.06	0.95	0.95	0.00